Therapeutic Advances in Thrombosis

Sheikh Mohammed Shariful Islam
Center for Control of Chronic Diseases (CCCD), International Center for Diarrhoeal Disease Research (ICDDR,B), Dhaka, and Center for International Health (CIH), Ludwig-Maximilians-Universität (LMU), Munich, Germany.

(Cardiovasc. j. 2015; 7(2): 166-167)

Therapeutic Advances in Thrombosis, Second Edition, is an essential reading for all cardiologists, hematologists, physicians and hospital pharmacists dealing with prognosis and intervention in preventing thrombosis in a variety of patients. It offers a comprehensive discussion of the way in which treatment strategy varies depending on the specific situation of the patient, and should be tailored to the patient’s specific condition. All chapters fully explore the clinical trial designs and outcomes for that particular treatment therapy, as well as containing the relevant ACC/AHA guidelines.
Managing patients with thrombotic vascular disease is complex and challenging: Ischemic vascular disease remains a complicated interplay of atherosclerosis and thrombosis—even with the evolution in our understanding of the pathobiology of thrombosis. Over the last few years, there has been tremendous growth in therapeutic options which are quickly finding their place in daily practice, including a remarkable expansion in the number of intravenous and oral antithrombotic agents and new antiplatelet agents.

This book is written and edited by today’s leading international physicians with the very latest in medical and surgical advances in antithrombotic therapies. It covers virtually all aspects of venous and arterial thrombotic disease and the corresponding therapies, strategies to manage specific clinical conditions and how to tailor treatment to individual patient needs, updated chapters covering thrombolysis in ST-elevated myocardial infarctions; thrombosis in patients with diabetes, pregnancy, and renal dysfunction and special emphasis on the pharmacology of novel anticoagulants and their practical use in venous thromboembolism and atrial fibrillation.

The second edition of “Therapeutic Advances in Thrombosis” provides physicians and cardiologists with the very latest in medical and surgical advances in anti-thrombotic therapies. This new edition covers evidence-based topics, including: the use of aspirin for primary and secondary prophylaxis, platelet inhibitors, glycoprotein IIb and IIIa inhibitors, pentasaccharides and oral direct thrombin inhibitors.

Therapeutic Advances in Thrombosis, second edition, also discusses the management of specific clinical conditions such as pulmonary embolism, atrial fibrillation, stroke and diabetes, or as an adjunct to other procedures such as PCI.